Ultragenyx Pharma (RARE) Tops Q2 EPS by $1.95, Revenue Beat; Offers FY20 Crysvita Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 17.16 +0.53 (3.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.63 | 52 Week High | $117.12 | |||
| Open | $17.04 | 52 Week Low | $46.52 | |||
| Day High | $17.67 | P/E | N/A | |||
| Day Low | $16.23 | EPS | $-1.97 | |||
| Volume | 7,330,251 | |||||
